Wikipedia -WSS

Wikipedia

author：leisure time 2025-08-11 11:45:56 - browse：6579

Amylyx founders — Justin Klee, left, and Joshua Cohen, both co-founders and co-CEO's of Amylyx Pharmaceuticals. Kayana Szymczak for STAT

The Food and Drug Administration has reversed an internal decision and will now review an experimental treatment for amyotrophic lateral sclerosis — a victory for ALS patients and advocates who have been pressuring regulators to act with more urgency against the fatal, neurodegenerative disease.

Amylyx Pharmaceuticals, a Cambridge, Mass.-based drug maker, said Wednesday that it will submit an application for its ALS treatment, called AMX0035, “in the coming months.”

The filing will be based largely on a single clinical trial of AMX0035 completed one year ago that showed a significant slowing of disease progression in patients with ALS. It’s the same study that FDA officials told Amylyx last April was encouraging, but not convincing enough to review for approval on its own. The company was told by FDA staff to conduct another study, gather more positive data, and then file for approval.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： Achieving telehealth equity for people with hearing loss

WSS

Pharma’s losing bet in New Jersey

Hospitals need to get ahead of regulations on climate change

Bubonic plague hit France in 1720. Officials dithered. Sound familiar?

U.S. death rates show how politics are affecting public health

The HPV vaccine prevents cancer in men, too. Why do so few people get it?

NEJM study measures Covid brain fog, impact on IQ

Wikipedia

Wikipedia

focus

Cancer drug shortages should be causing more outrage

Lawsuit challenges CMS nursing home minimum staffing rule

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Pfizer is about to make a big push in cancer. Will investors listen?

Hollywood unions extend contract negotiations for actors

Readout Newsletter: GSK, Viking Therapeutics, mifepristone news

Drug repurposing or repositioning? The language matters

Medical students need to learn the potent medicine of empathy

Walensky prepares to leave CDC — and Congress — behind

NEJM study measures Covid brain fog, impact on IQ

leisure time

Pfizer is about to make a big push in cancer. Will investors listen?

Laying a path for careers in science

Cholera vaccine supplies dangerously low, outbreaks surging

STAT Madness 2024: Meet the contenders

Unmasking the 'centricity' illusion in clinical trials

Color Health wants to make cancer screenings convenient

focus

hotspot

leisure time

hotspot